Details

Autor(en) / Beteiligte

• Lacro, Ronald V
• Dietz, Harry C
• Sleeper, Lynn A
• Yetman, Anji T
• Bradley, Timothy J
• Colan, Steven D
• Pearson, Gail D
• Selamet Tierney, E. Seda
• Levine, Jami C
• Atz, Andrew M
• Benson, D. Woodrow
• Braverman, Alan C
• Chen, Shan
• De Backer, Julie
• Gelb, Bruce D
• Grossfeld, Paul D
• Klein, Gloria L
• Lai, Wyman W
• Liou, Aimee
• Loeys, Bart L
• Markham, Larry W
• Olson, Aaron K
• Paridon, Stephen M
• Pemberton, Victoria L
• Pierpont, Mary Ella
• Pyeritz, Reed E
• Radojewski, Elizabeth
• Roman, Mary J
• Sharkey, Angela M
• Stylianou, Mario P
• Wechsler, Stephanie Burns
• Young, Luciana T
• Mahony, Lynn

Titel

Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome

Ist Teil von

• The New England journal of medicine, 2014-11, Vol.371 (22), p.2061-2071

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• In this study, children and young adults with Marfan's syndrome were randomly assigned to receive atenolol or losartan and were followed for 3 years. There was no significant difference between the two groups in the rate of aortic-root dilatation. Marfan's syndrome is an autosomal dominant disorder of connective tissue affecting approximately 1 in 5000 people. 1 Cardiovascular disease, mainly progressive aortic-root dilatation and dissection, is the leading cause of death in Marfan's syndrome. After an open-label, randomized trial comparing propranolol with no therapy, published in 1994, showed a reduced rate of aortic enlargement among treated patients, beta-adrenergic receptor antagonists (beta-blockers) became the mainstay of medical management. 2 Current management includes serial cardiac imaging, exercise restriction, administration of beta-blockers, and elective aortic-root replacement. 3 Although early diagnosis and refined medical and surgical treatment have improved survival, patients with Marfan's syndrome continue to have . . .